News

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger. The stock has fallen roughly 15% since early July, when two...

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock’s biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed […]

AstraZeneca (LSE:AZN) is back in focus after a senior source told Reuters that there are no ongoing merger discussions with Bristol Myers Squibb, reversing earlier headlines around a potential $400b pharmaceutical tie up. See our latest analysis for AstraZeneca. The clarification on merger talks comes after a sharp swing in AstraZeneca’s share price, which fell over recent weeks with a 30 day share price return of 17.5% decline and a year to date share price return of 12.8% decline. In...

Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.

Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.

According to a Reuters report, a senior source denied merger discussions between AstraZeneca and Bristol Myers Squibb.

AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are “no discussions” between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The report eased concerns surrounding a deal that, if completed, would have created a pharmaceutical group valued at close to $400 billion.

A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers

Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.

AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.

Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a...

AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. The transaction, if completed, would rank among the largest in the sector and could significantly affect competitive positions in oncology. Regulators are expected to review any agreement closely due to overlapping product portfolios. AstraZeneca is a global pharmaceutical company with a significant focus on...

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script.

Investors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.

The UK drugmaker is reportedly talking to Bristol Myers Squibb about a nearly $400 billion tie-up, but investors are struggling to diagnose the logic.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.

One of the largest global pharma companies would be created if a deal were to materialise.

BMY surged roughly 6% in premarket trading on the news before fading; the stock is now trading near flat. The asymmetric price reaction captures the market's immediate verdict: AZN shareholders see a value-destructive deal, while BMY holders see a potential premium exit.

European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa

Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb.

A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.

Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. If agreed, the combined group would rank among the largest pharmaceutical companies globally. The discussions are described as preliminary and no formal deal has been announced as at 31 July 2026. Bristol-Myers Squibb, traded as NYSE:BMY, is back in focus as investors consider what a tie up with AstraZeneca could mean for the $65.31 share price. The stock has logged returns of 5.2% over...